# Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.

> **NCT02445976** · PHASE2 · COMPLETED · sponsor: **Innocrin Pharmaceutical** · enrollment: 197 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Seviteronel: given orally once daily in 28-day cycles

## Key facts

- **NCT ID:** NCT02445976
- **Lead sponsor:** Innocrin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2018-12
- **Final completion:** 2019-01
- **Target enrollment:** 197 (ESTIMATED)
- **Last updated:** 2019-02-01

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02445976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02445976, "Once-daily Oral Seviteronel in Patients With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone.". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02445976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*